N. Girard

N. Le Stang, N. Girard, A. Nicholson, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.

S. Armato, P. Courtiol, N. Girard, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease

N. Girard, F. Galateau-Sallé, C. Caux, 2018, bioRxiv.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in non-small cell lung cancer patients

Thomas Dupic, T. Mora, N. Girard, 2020 .

ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting

N. Girard, A. Nicholson, M. Kurrer, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Regulatory mechanism of transforming growth factor beta receptor type II degradation by interleukin-1 in primary chondrocytes.

N. Girard, P. Galéra, K. Boumediene, 2012, Biochimica et biophysica acta.

Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma

N. Girard, M. Brevet, P. Clézardin, 2021, Journal of bone oncology.

[Thymoma and autoimmune diseases].

N. Girard, H. Frih, P. Petiot, 2018, La Revue de medecine interne.

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

N. Girard, P. Baas, A. Scherpereel, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphoma, Lymphoproliferative Diseases, and Other Primary Malignant Tumors

N. Girard, E. Brambilla, J. Cordier, 2010 .

European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review

N. Girard, J. Feliciano, K. Davis, 2021, Drugs - Real World Outcomes.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung

N. Girard, S. Lantuejoul, J. Mazières, 2017, Oncotarget.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

N. Girard, O. Molinier, M. Denis, 2019, Clinical lung cancer.

3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells

N. Girard, A. Llombart‐Bosch, H. Bénateau, 2014, PloS one.

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.

N. Girard, M. Carton, R. Gervais, 2021, Lung cancer.

54 – Rare Primary Lung Tumors

N. Girard, E. Brambilla, J. Cordier, 2016 .

Type II TGFβ receptor modulates chondrocyte phenotype

N. Girard, P. Galéra, K. Boumediene, 2012, AGE.

Second‐Line Treatment Selection in Patients With Non–Small‐Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians

N. Girard, D. Heigener, D. Cortinovis, 2017, Clinical lung cancer.

N2 Nodal Involvement in Multiple Primary Lung Cancer: Response

N. Girard, 2013 .

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

M. Soussan, N. Girard, L. Mezquita, 2020, Cancers.

Strategies of Lymph Node Dissection During Sublobar Resection for Early-Stage Lung Cancer

N. Girard, D. Gossot, G. Boddaert, 2021, Frontiers in Surgery.

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

Fergus Gleeson, Heber MacMahon, Jin Mo Goo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survival.

N. Girard, D. Gossot, P. Girard, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Reply to "Better Prognostic Models May Result in Improved Patient Selection for Adjuvant Therapies After Complete Resection of Solitary Fibrous Tumors of the Pleura".

N. Girard, O. Bylicki, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oligometastases for Clinicians: Size Matters.

N. Girard, D. Gossot, P. Girard, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

N. Girard, J. Soria, E. Lanoy, 2018, European journal of cancer.

Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice

N. Girard, J. Dalphin, A. Depierre, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pulmonary artery sarcoma, a paradigm of orphan thoracic oncology.

N. Girard, F. Giammarile, D. Revel, 2009, Presse medicale.

Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study

N. Girard, P. Vanhems, V. Cottin, 2011, PloS one.

Neuroendocrine tumors of the thymus: the oncologist point of view.

N. Girard, 2017, Journal of thoracic disease.

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.

N. Girard, J. Mazières, C. Lindsay, 2016, Lung cancer.

Standard-fractionated radiotherapy for optic nerve sheath meningioma: visual outcome is predicted by mean eye dose.

N. Girard, A. Vighetto, C. Tilikete, 2012, International journal of radiation oncology, biology, physics.

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.

N. Girard, F. Bertucci, P. Gestraud, 2022, Lung cancer.

Cardiovascular effects of innovative therapies in lung cancer

N. Girard, A. Toffart, H. Pluchart, 2020, Cardiovascular Complications of Respiratory Disorders.

Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.

N. Girard, T. Molina, A. Marx, 2015, Pathology, research and practice.

Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study

N. Girard, P. Fournel, R. Descourt, 2022, Therapeutic advances in medical oncology.

Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers

N. Girard, M. Ladanyi, C. Begg, 2009, Clinical Cancer Research.

Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

N. Girard, M. Ladanyi, V. Rusch, 2010, Chest.

Réarrangements de ALK, diagnostic, traitement, perspectives

N. Girard, M. Émery, 2014 .

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

N. Girard, J. Timsit, D. Moro-Sibilot, 2014, Intensive Care Medicine.

c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

N. Girard, S. Lantuejoul, J. Mazières, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors

N. Girard, M. Brevet, P. Bringuier, 2020, Journal of thoracic disease.

Assessing the Multimodal Management of Advanced Solitary Fibrous Tumors of the Pleura in a Routine Practice Setting

N. Girard, J. Blay, J. Mazières, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.

N. Girard, F. Mornex, J. Delpero, 2005, Seminars in radiation oncology.

Thymic epithelial tumours: from basic principles to individualised treatment strategies

N. Girard, 2013, European Respiratory Review.

The role of radiotherapy in the management of thymic tumors.

N. Girard, F. Mornex, 2011, Thoracic surgery clinics.

Thymoma: a focus on current therapeutic management.

N. Girard, P. V. Van Schil, P. van Houtte, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Focus on Current Therapeutic Management

N. Girard, P. Houtte, P. Schil, 2009 .

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

N. Girard, J. Mazières, G. Zalcman, 2020, Respiratory Medicine and Research.

Case presentations and recommendations from the 2018 ITMIG Annual Meeting

N. Girard, F. Detterbeck, M. Marino, 2020, Mediastinum.

Case presentation and recommendations from the April 2019 ITMIG tumor board: an international multidisciplinary team

N. Girard, F. Detterbeck, M. Marino, 2019, Mediastinum.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

C. Dooms, N. Girard, H. Gietema, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

E. Quoix, B. Mennecier, G. R. Ferretti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical practices for non-neoplastic thymic lesions: Results from a multidisciplinary cohort.

N. Girard, F. Tronc, J. Maury, 2022, Lung cancer.

The Distribution of Mediastinal Lesions across Multi-Institutional, International, Radiology Databases.

N. Girard, E. Klang, M. Revel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer.

N. Girard, A. Foucaut, C. Fournel, 2018, Lung cancer.

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

N. Girard, A. Gavin, H. Comber, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey.

N. Girard, D. de Ruysscher, S. Lantuejoul, 2022, Lung cancer.

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

N. Girard, S. Broderick, T. Mitsudomi, 2021 .

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

N. Girard, S. Lantuejoul, S. Novello, 2018, European journal of cancer.

Assessment of the ITMIG Statement on the WHO Histological Classification and of the Eighth TNM Staging of Thymic Epithelial Tumors of a Series of 188 Thymic Epithelial Tumors

N. Girard, F. Thivolet-Béjui, A. Meurgey, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)

N. Girard, O. Molinier, D. Moro-Sibilot, 2017 .

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

N. Girard, A. Stenzinger, C. Swanton, 2019 .

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

N. Girard, F. Galateau-Sallé, S. Lantuejoul, 2018, Annales de pathologie.

Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature

P. Grenier, N. Girard, J. Piette, 2016, Immunologic Research.

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1

N. Girard, F. Galateau-Sallé, T. Molina, 2019, Biomarker Research.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

[Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France].

N. Girard, B. Besse, J. Hadoux, 2012, Bulletin du cancer.

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

N. Girard, E. Devin, J. Muir, 2022, The Lancet. Oncology.

Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study

N. Girard, L. Delrieu, C. Bouleuc, 2022, Cancers.

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers

N. Girard, S. Ramkissoon, A. Schrock, 2022, The oncologist.

Thymic tumours and their special features

N. Girard, C. Basse, 2021, European Respiratory Review.

An overview: ongoing systemic therapy trials in thymic epithelial tumors around the world-will anything “hit”?

N. Girard, C. Merveilleux du Vignaux, 2021, Mediastinum.

Immune checkpoints in thymic epithelial tumors: challenges and opportunities

N. Girard, 2019, Immuno-oncology technology.

Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?

N. Girard, 2019, Mediastinum.

Thymic malignancies: emerging systemic therapies.

N. Girard, 2019, Current opinion in oncology.

Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

N. Girard, T. Molina, L. Thiberville, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas

N. Girard, C. Leroux, F. Tronc, 2018, bioRxiv.

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review.

N. Girard, C. Hennequin, F. Mornex, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.

N. Girard, I. Durand-zaleski, J. Penrod, 2022, Lung cancer.

EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents.

N. Girard, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group.

N. Girard, J. Blay, F. Collin, 2014, European journal of cancer.

1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)

N. Girard, O. Molinier, D. Moro-Sibilot, 2017 .

Thymic Epithelial Tumor‐Associated Cytopenia: A 10‐Year Observational Study in France

N. Girard, J. Viallard, B. Besse, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic treatment for thymic malignancies

N. Girard, C. Merveilleux du Vignaux, 2016, Current opinion in oncology.

胸腺恶性肿瘤化疗的相关定义和策略

N. Girard, H. Wakelee, Gregory Riely, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Radiation Therapy in Thymoma

N. Girard, 2018, Radiation Oncology.

Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

N. Girard, K. O'Byrne, S. Ramalingam, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC

N. Girard, I. Bièche, C. Callens, 2020, JTO clinical and research reports.

Retroperitoneal fibrosis: a rare vascular and immune entity disclosed by chronic lombalgia.

N. Girard, E. Vignon, C. Alexandre, 2007, Joint, bone, spine : revue du rhumatisme.

Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report.

N. Girard, V. Cottin, J. Cordier, 2009, Presse medicale.

Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study

N. Girard, T. Molina, A. Marx, 2021, Virchows Archiv.

Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study.

N. Girard, T. Molina, A. Marx, 2020, European journal of cancer.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).

N. Girard, C. Escriu, Shin‐Yup Lee, 2021, Lung cancer.

Unusual Bilateral Acinar Nodules: Case for Diagnosis

N. Girard, V. Cottin, F. Thivolet-Béjui, 2009, Respiration.

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases

N. Girard, A. Beddok, P. Verrelle, 2022, Biomedicines.

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

N. Girard, O. Molinier, J. Mazières, 2017 .

Subtotal Pleurectomy with Intrathoracic Chemo Hyperthermia (HITHOC) for IVa Thymomas: De Novo Versus Recurrent Pleural Disease

N. Girard, P. Rosamel, S. Couraud, 2022, Cancers.

Optimal management of thymic malignancies: current perspectives

N. Girard, F. Tronc, J. Maury, 2019, Cancer management and research.

Thymic Tumors: Revisiting Autoimmunity to Give a Chance to Immunotherapy.

N. Girard, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Thymic tumours: an update.

N. Girard, B. Besse, V. Polo, 2013, Presse medicale.

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.

N. Girard, H. Blons, J. Trédaniel, 2019, Lung cancer.

Rapid detection of EGFR mutations in decalcified lung cancer bone metastasis

N. Girard, M. Brevet, C. Confavreux, 2020, Journal of Bone Oncology.

The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors

G. Giaccone, N. Girard, A. Nicholson, 2020, Journal of Thoracic Oncology.

The IASLC Thymic Tumors Staging Project. The Impact of the 8th Edition of the UICC/AJCC TNM Stage Classification of Thymic Tumors: Results of a Survey.

G. Giaccone, N. Girard, A. Nicholson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.

N. Girard, S. Lantuejoul, S. Novello, 2019, European journal of cancer.

MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts

N. Girard, H. Gietema, G. Scagliotti, 2018, Journal of Thoracic Oncology.

MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC

N. Girard, A. Dingemans, S. Lantuejoul, 2018, Journal of Thoracic Oncology.

Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study.

N. Girard, R. Fietkau, B. Markman, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC).

N. Girard, M. Brevet, P. Clézardin, 2014, BoneKEy reports.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Immune reconstitution inflammatory syndrome mimicking relapsing cryptococcal meningitis in a renal transplant recipient

N. Girard, S. Ranque, Y. Berland, 2011, Transplant infectious disease : an official journal of the Transplantation Society.

Jaagsiekte Sheep Retrovirus (JSRV): from virus to lung cancer in sheep.

N. Girard, V. Cottin, T. Greenland, 2007, Veterinary research.

Thymoma associated with autoimmune diseases: 85 cases and literature review.

N. Girard, H. Frih, P. Petiot, 2016, Autoimmunity reviews.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Elisabeth Brambilla, Sergio Peralta, Anna Martínez-Cardús, 2018, The Lancet. Respiratory medicine.

Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.

N. Le Stang, N. Girard, F. Galateau-Sallé, 2020, Archives of pathology & laboratory medicine.

New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts

N. Girard, S. Lantuejoul, F. Damiola, 2020, Translational lung cancer research.

PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee.

N. Girard, A. Nicholson, A. Borczuk, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

Aurélie A G Gabriel, N. Le Stang, N. Girard, 2019, Nature Communications.

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

N. Girard, J. Blay, F. Galateau-Sallé, 2015, Nature Genetics.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Clement Adebamowo, Ritika Kundra, Steven J. M. Jones, 2018, Cell reports.

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

N. Girard, M. Ahn, Melissa L. Johnson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

N. Girard, Keunchil Park, L. Paz-Ares, 2018 .

Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

N. Girard, I. Bièche, F. André, 2021, ESMO open.

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.

N. Girard, S. Ou, L. Bazhenova, 2022, Lung cancer.

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

N. Girard, K. Samitas, D. Planchard, 2022, JTO clinical and research reports.

Molecular Targetable Pathways – EGFR

N. Girard, S. Popat, Richard W. Lee, 2021 .

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.

N. Girard, L. Bazhenova, S. Gadgeel, 2021, Lung cancer.

Histone methylases as novel drug targets: developing inhibitors of EZH2.

N. Girard, C. Bazille, K. Boumediene, 2014, Future medicinal chemistry.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

Clinical Applications of Kinase Inhibitors in Solid Tumors

N. Girard, W. Pao, 2010 .

Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies

N. Girard, M. Kris, V. Rusch, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients

N. Girard, D. Gossot, P. Validire, 2021, Frontiers in Immunology.

Disentangling heterogeneity of Malignant Pleural Mesothelioma through deep integrative omics analyses

Erik N. Bergstrom, P. Courtiol, C. Maussion, 2021, bioRxiv.

Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients

N. Girard, M. Brevet, P. Bringuier, 2020, Journal of thoracic disease.

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

C. Schumann, N. Girard, G. Scagliotti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.

N. Girard, G. Milano, M. Brevet, 2018, Lung cancer.

Other signalization targets

N. Girard, 2013, Targeted Oncology.

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN

N. Girard, J. Blay, R. Erlich, 2020, ESMO Open.

Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes

N. Girard, G. Ciliberto, P. Visca, 2020, Frontiers in Oncology.

Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas

N. Girard, A. Lash, A. Viale, 2009, Clinical Cancer Research.

Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

N. Girard, A. Marx, S. Peters, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

OA 03.01 Prevalence of Autoimmune Diseases in Thymic Epithelial Tumors (TET) Insights from RYTHMIC

N. Girard, L. Thiberville, J. Mazières, 2017 .

Novel Agents in the Treatment of Thymic Malignancies

N. Girard, J. Maury, C. Merveilleux du Vignaux, 2017, Current Treatment Options in Oncology.

The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

N. Girard, M. Kurrer, N. Harris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

N. Girard, S. Novello, B. Besse, 2021, Clinical lung cancer.

The IASLC Thymic Epithelial Tumors Staging Project: unresolved issues to be addressed for the next 9th edition of the TNM classification of malignant tumors.

G. Giaccone, N. Girard, A. Nicholson, 2022, Journal of Thoracic Oncology.

LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

N. Girard, R. Stahel, S. Cedrés, 2021, Annals of Oncology.

State of the Art of Genetic Alterations in Thymic Epithelial Tumors

N. Girard, A. Marx, A. Rajan, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network.

N. Girard, T. Molina, L. Thiberville, 2021, European journal of cancer.

1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)

N. Girard, T. Molina, L. Thiberville, 2020 .

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

N. Girard, A. Cazes, J. Mazières, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

N. Girard, A. Viale, M. Ladanyi, 2010, Clinical Cancer Research.

Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer

T. Mora, N. Girard, A. Walczak, 2021, Science Immunology.

Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).

N. Girard, E. Brambilla, J. Timsit, 2014, Lung cancer.

Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.

N. Girard, S. Ou, L. Bazhenova, 2022, Clinical lung cancer.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

Nicolas Girard, N. Girard, 2012, European Respiratory Journal.

Chemotherapy and targeted agents for thymic malignancies

N. Girard, 2012, Expert review of anticancer therapy.

Targeted therapies for thymic malignancies.

N. Girard, 2011, Thoracic surgery clinics.

Thymic Tumors: Relevant Molecular Data in the Clinic

N. Girard, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Thymic malignancies: Twisting between autoimmunity and immunotherapy.

N. Girard, 2017, Lung cancer.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?

N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Chemotherapy definitions and policies for thymic malignancies].

N. Girard, H. Wakelee, Gregory Riely, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Use of immune checkpoint inhibitors in thymic epithelial tumors

N. Girard, 2018 .

Positron Emission Tomography in Thymic Tumors: Analysis Using a Prospective Research Database.

N. Girard, A. Catlin, F. Detterbeck, 2017, The Annals of thoracic surgery.

Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

N. Girard, L. Thiberville, B. Dubray, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50.

N. Girard, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparisons of microRNA Patterns in Plasma before and after Tumor Removal Reveal New Biomarkers of Lung Squamous Cell Carcinoma

N. Girard, Z. Herceg, V. Krutovskikh, 2013, PloS one.

Reply to "better prognostic models may result in improved patient selection for adjuvant therapies after complete resection of solitary fibrous tumors of the pleura".

N. Girard, O. Bylicki, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

G. Wainrib, P. Courtiol, C. Maussion, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience.

N. Girard, K. Oselin, K. Lepik, 2019, Journal of thoracic disease.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Treatment options for stage IVA thymic malignancies

N. Girard, 2019, Mediastinum.

Cytoreductive Pleurectomy and Intrathoracic Chemohyperthermia for Pleural Relapse of Thymomas.

N. Girard, P. Rosamel, S. Collaud, 2019, The Annals of thoracic surgery.

Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma.

N. Girard, P. Souquet, C. Leroux, 2017, Lung cancer.

The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.

N. Girard, K. Boumediene, C. Baugé, 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.

N. Girard, V. Durieux, T. Berghmans, 2021, Lung cancer.

Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective

N. Girard, 2013, Expert review of anticancer therapy.

Systemic treatments for thymoma and thymic carcinoma: A systematic review.

N. Girard, V. Durieux, J. Lafitte, 2018, Lung cancer.

[NSCLC and new oncogenic mutations: Diagnosis and perspectives].

N. Girard, D. Moro-Sibilot, J. Remon, 2021, Revue des maladies respiratoires.

Driver mutations as predictive biomarkers in lung cancer

N. Girard, 2012, Current Respiratory Care Reports.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

N. Girard, J. Mazières, D. Moro-Sibilot, 2017, Oncotarget.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

N. Girard, D. Planchard, G. Zalcman, 2015, Expert review of anticancer therapy.

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

N. Girard, D. Planchard, G. Zalcman, 2014, Bulletin du cancer.

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

N. Girard, R. Schilsky, J. Lee, 2022, Cancer medicine.

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

N. Girard, Keunchil Park, L. Paz-Ares, 2020, Frontiers in Oncology.

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

N. Girard, 2018, Future oncology.

Biology of Human Tumors Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers : A Proof-of-Concept Study

N. Girard, T. Schuster, M. Olivier, 2014 .

UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN).

N. Girard, A. Addeo, K. Cuppens, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases

William Pao, Valerie Rusch, Charuhas Deshpande, 2009, The American journal of surgical pathology.

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

N. Girard, T. Schuster, M. Olivier, 2014, Clinical Cancer Research.

Infections opportunistes et sarcoïdose

N. Girard, V. Cottin, A. Hot, 2004 .

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

N. Girard, O. Molinier, P. Souquet, 2016, Lung cancer.

Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates.

N. Girard, 2019, Future oncology.

Highlights of the 2nd European Lung Cancer Conference

N. Girard, F. Mornex, 2010, Expert review of anticancer therapy.

Transsternal transpericardial closure of a postpneumonectomy bronchial fistula in a patient who underwent pneumonectomy because of a war injury

N. Girard, J. Gamondès, F. Tronc, 2009, General thoracic and cardiovascular surgery.

Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial.

N. Girard, C. Trépo, F. Mornex, 2006, International journal of radiation oncology, biology, physics.

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard, C. Lepage, J. Mazières, 2021, Annals of Oncology.

From Cancer Mimicking Orphan Lung Disease to Orphan Thoracic Oncology

N. Girard, V. Cottin, J. Cordier, 2015 .

Respiratory failure with diffuse bronchiectases and cryoglobulinaemia

N. Girard, V. Cottin, A. Vasiljevic, 2008, European Respiratory Journal.

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics

N. Girard, G. Rossi, S. Novello, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

N. Girard, D. Planchard, T. Ciuleanu, 2022, Journal of Clinical Oncology.

[Mucosa-associated lymphoid tissue-derived (MALT) lymphoma].

N. Girard, J. Cordier, G. Salles, 2016, Revue de pneumologie clinique.

[Mucosa-associated lymphoid tissue-derived (MALT) lymphoma].

N. Girard, J. Cordier, G. Salles, 2016, Revue de pneumologie clinique.

From the old to the new: The EURACAN Project

N. Girard, 2018 .

Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines

N. Girard, K. Boumediene, C. Baugé, 2020, Journal of bone oncology.

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.

N. Girard, B. Milleron, J. Douillard, 2010, Lung cancer.

RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection.

N. Girard, T. Molina, L. Thiberville, 2021, Clinical lung cancer.

Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management.

N. Girard, M. Brevet, P. Souquet, 2019, Joint, bone, spine : revue du rhumatisme.

N. Girard, A. Stenzinger, C. Swanton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymph Node Dissection in Thymoma: Is it worth it?

N. Girard, F. Mornex, S. Collaud, 2021, Lung cancer.

Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.

N. Girard, M. Ychou, J. Scoazec, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Hadrontherapy for Thymic Epithelial Tumors: Implementation in Clinical Practice

N. Girard, B. Jereczek-Fossa, A. Mirandola, 2021, Frontiers in Oncology.

Ocular and Orbital Tumors: Viewpoint-Fractionated Radiation

N. Girard, A. Vighetto, F. Mornex, 2015 .

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

N. Girard, F. Bidard, D. Ricard, 2019, Journal of Immunotherapy for Cancer.

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.

N. Girard, P. Souquet, P. Bringuier, 2016, Lung cancer.

FP07.12 Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets

N. Girard, S. Ou, L. Bazhenova, 2021 .

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

N. Girard, Dohoung Kim, B. Cho, 2021 .

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome

N. Girard, D. Gossot, P. Validire, 2018, Oncoimmunology.

Treatment and outcome of a patient with radiation-induced organizing pneumonia in the context of coronavirus disease 2019 (COVID-19)

N. Girard, V. Servois, A. Beddok, 2021, Radiotherapy and Oncology.

Is the treatment of hepatocellular carcinoma on the waiting list necessary?

N. Girard, R. Lencioni, R. Poon, 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center

N. Girard, A. Livartowski, C. Daniel, 2021, Lung Cancer.

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

N. Girard, G. Ferretti, E. Brambilla, 2014, BMC Cancer.

CARMN‐NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract

N. Girard, J. Coindre, J. Emile, 2021, Genes, chromosomes & cancer.

Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.

N. Girard, M. Ychou, M. Ducreux, 2006, International journal of radiation oncology, biology, physics.

Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.

N. Girard, D. Gossot, P. Girard, 2021, Lung cancer.

Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers.

N. Girard, E. Ollier, M. Brevet, 2018, Bone.

Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.

N. Girard, P. Souquet, F. Mornex, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymomas.

N. Girard, F. Tronc, J. Maury, 2017, Journal of thoracic disease.

Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study.

N. Girard, S. Hervé, V. Bouvier, 2019, Surgery.

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

N. Girard, D. Planchard, B. Besse, 2021, Cancers.

Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series

N. Girard, F. Berger, J. Cordier, 2017, Hematological oncology.

Regulation and Role of TGFβ Signaling Pathway in Aging and Osteoarthritis Joints.

N. Girard, C. Bazille, K. Boumediene, 2014, Aging and disease.

PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy.

N. Girard, S. Peters, R. Fietkau, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy for locally advanced non-small cell lung cancer.

N. Girard, F. Mornex, 2009, European journal of cancer.

1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

N. Girard, S. Peters, R. Fietkau, 2021, Annals of Oncology.

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

N. Girard, S. Broderick, T. Mitsudomi, 2022, Cancer Research.

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

N. Girard, A. Cortot, D. Cozzone, 2018, ESMO Open.

Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.

N. Girard, L. Mezquita, C. Chouaid, 2021, Lung cancer.

A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas database study.

N. Girard, Y. Hao, F. Detterbeck, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.

N. Girard, T. Filleron, H. Léna, 2023, Respiratory medicine and research.

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.

N. Girard, S. Lantuejoul, J. Mazières, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in France.

N. Girard, F. Gueyffier, P. Souquet, 2013, Clinical lung cancer.

Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art.

N. Girard, F. Mornex, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[Opportunistic infections and sarcoidosis].

N. Girard, V. Cottin, A. Hot, 2004, Revue des maladies respiratoires.

Thymic tumors: adopting an orphan thoracic tumor as a model of personalized medicine.

N. Girard, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening.

N. Girard, F. Laurent, M. Revel, 2021, Diagnostic and interventional imaging.

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.

N. Girard, E. Letouzé, S. Lantuejoul, 2022, Lung cancer.

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study

N. Girard, M. Carton, E. Giroux-Leprieur, 2021, Cancer Immunology, Immunotherapy.

Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)

N. Girard, Keunchil Park, T. Mok, 2019, Annals of Oncology.

1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)

N. Girard, M. Hochmair, S. Popat, 2021, Annals of Oncology.

Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)

N. Girard, S. Mathoulin-Pélissier, M. Wislez, 2022, Cancers.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

N. Girard, J. Mazières, P. Dubray-Longeras, 2022, European journal of cancer.

Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

N. Girard, J. Lee, B. Leyland-Jones, 2019, Annals of Oncology.

3023 Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network

N. Girard, B. Besse, J. Menis, 2015 .

[Chemoradiation for locally advanced non-small cell lung cancer].

N. Girard, F. Mornex, 2007, Cancer Radiothérapie.

Topics in thoracic oncology: from surgical resection to molecular dissection

N. Girard, G. Zalcman, 2013, European Respiratory Review.

Type II TGFβ receptor modulates chondrocyte phenotype

N. Girard, P. Galéra, K. Boumediene, 2013, AGE.

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report

N. Girard, M. Luporsi, Q. Thomas, 2022, Frontiers in Oncology.

Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network.

N. Girard, T. Molina, L. Thiberville, 2020 .

Thymic Carcinomas - A Concise Multidisciplinary Update on Recent Developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.

N. Girard, A. Nicholson, A. Marx, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer

M. Soussan, N. Girard, C. Chouaid, 2020, Annals of Nuclear Medicine.

79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

N. Girard, S. Siva, A. Allen, 2021 .

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

N. Girard, R. Boidot, J. Iovanna, 2022, BMC cancer.

Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients

N. Girard, A. Ravel, V. Cottin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient

N. Girard, F. Fiteni, Q. Thomas, 2021, Medicine.

MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients

N. Girard, O. Molinier, F. Barlesi, 2019, Journal of Thoracic Oncology.

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

N. Girard, B. Chauffert, M. Ychou, 2010, International journal of radiation oncology, biology, physics.

Anti-inflammatory effects of an injectable copolymer of fatty acids (Ara 3000 beta®) in joint diseases

N. Girard, K. Boumediene, C. Baugé, 2015, Journal of Inflammation.

Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care.

N. Girard, M. Pérol, A. Toffart, 2021, Bulletin du cancer.

Is There a Role for Postoperative Radiotherapy in Elderly Patients with Early-Stage Non-small Cell Lung Cancer?

N. Girard, F. Mornex, 2013 .

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival

N. Girard, R. Schilsky, R. Berger, 2021, npj Precision Oncology.

MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations

N. Girard, S. Ou, L. Bazhenova, 2021 .

Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.

N. Girard, L. Thiberville, B. Besse, 2021 .

OA 16.03 Recurrences and 2nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery

N. Girard, J. Lafitte, J. Muir, 2017 .

Identification of an easy to use 3D culture model to investigate invasion and anticancer drug response in chondrosarcomas

N. Girard, C. Bazille, K. Boumediene, 2017, BMC Cancer.

Blocked expression of key genes of the angiogenic pathway in JSRV-induced pulmonary adenocarcinomas

N. Girard, C. Leroux, J. Mornex, 2017, Veterinary Research.

Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases.

N. Girard, J. Honnorat, V. Cottin, 2006, Lung cancer.

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.

N. Girard, C. Maritaz, D. Moro-Sibilot, 2020, Future oncology.

[Stage IIIB non-small cell lung cancer. Optimization of radiotherapy in lung cancer: some interesting questions to be solved].

N. Girard, F. Mornex, 2006, Revue des maladies respiratoires.

Clubbing, Arthralgia and a Large Intrathoracic Mass

N. Girard, V. Cottin, F. Thivolet-Béjui, 2012, Respiration.

How large databases may impact clinical practices for rare tumors-postoperative chemotherapy in thymic malignancies.

N. Girard, C. Merveilleux du Vignaux, 2016, Journal of thoracic disease.

[Rythmic-pathology: the French national pathology network for thymic epithelial tumours].

N. Girard, T. Molina, A. Marx, 2014, Annales de pathologie.

Proton Beam Therapy for Thymic Carcinoma with Pericardial Involvement

N. Girard, Y. Kirova, P. Loap, 2020, International journal of particle therapy.

Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

N. Girard, S. Broderick, K. Kerr, 2017 .

Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.

N. Girard, C. Basse, C. Merveilleux du Vignaux, 2017, Journal of Thoracic Oncology.

[Lung cancer: epidemiology and screening].

N. Girard, C. Merveilleux du Vignaux, S. Beaucaire-Danel, 2017, La Revue du praticien.

[Tolerance and efficacy of conformal radiotherapy for hepatocellular carcinoma in cirrhotic patients. Results of the French RTF1 phase II trial].

N. Girard, C. Trépo, F. Mornex, 2005, Cancer Radiothérapie.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

N. Girard, S. Lantuejoul, J. Mazières, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Optimal management of thymic malignancies: current perspectives

N. Girard, S. Collaud, F. Tronc, 2019 .

Chemotherapy definitions and policies for thymic malignancies.

N. Girard, H. Wakelee, Gregory Riely, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

N. Girard, E. Felip, Dong-Wan Kim, 2021 .

[Pulmonary metastases from malignant meningioma].

N. Girard, A. Vasiljevic, F. Tronc, 2010, Revue des maladies respiratoires.

Recurrent and metastatic carcinomas of the lacrimal gland: High frequency of ERBB2 driven disease.

N. Girard, V. Miller, S. Millis, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The Immune Landscape of Cancer.

James A. Eddy, David L. Gibbs, Christopher A. Miller, 2018, Immunity.

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

N. Girard, A. Gavin, H. Comber, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Crizotinib in ALK-positive lung cancer.

N. Girard, 2012, The Lancet. Oncology.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

N. Girard, M. Stern, F. Bidard, 2018, Nature Reviews Clinical Oncology.

[Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].

N. Girard, C. Confavreux, M. Kostine, 2021, Bulletin du cancer.

[Recommendations of French specialists on screening for lung cancer].

N. Girard, F. Laurent, M. Revel, 2021, Revue des maladies respiratoires.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

N. Girard, M. Fraga, M. Esteller, 2018, The Lancet. Respiratory medicine.

[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network].

N. Girard, T. Molina, A. Marx, 2020, Annales de pathologie.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?

N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

GGO and minimally invasive adenocarcinomas: how to deal with?

N. Girard, 2018, Journal of thoracic disease.